New Cases Of Non-melanoma Skin Cancer Research Articles

Profile of Non-Melanoma Skin Cancer and Malignant Melanoma at Dr. Mohammad Hoesin General Hospital Palembang from 2017 - 2019: A Retrospective Study

Background: Currently, there is an increasing trend in skin cancer incidence, especially non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), also malignant melanoma (MM), causing an increase in morbidity and mortality rates. The high treatment cost causes an economic burden of disease in the country and negatively impacts public health issues. This study aimed to determine the profile of NMSC and MM regarding the sex, age, occupation, location of the lesion, clinicohistopathological diagnosis of skin cancer in Dr. Mohammad Hoesin General Hospital Palembang January 2017-December 2019.
 Methods: A retrospective analytical observational study obtained from medical records of NMSC and MM patients in Dr. Mohammad Hoesin General Hospital Palembang from January 2017-December 2019 as confirmed using histopathological results from the Pathology Department.
 Results: There were 324 new cases of NMSC and MM, including BCC 162 cases (50%) and SCC 130 cases (40.1%), whereas MM 32 cases (9.9%). Women had a higher probability of developing skin cancer with a ratio of 1.13:1. The average age of skin cancer was between 55-64 years old (33.6%), with a mean age of 57 years old. There was a statistically significant relationship between gender, age, occupation, and areas of skin cancer against skin cancer. Furthermore, overexposure to ultraviolet (UV) radiation is related to high-risk occupations, including farmers (50%), while the most frequent location of skin cancer was the face (67.3%).
 Conclusion: Our study implicated a 1.5-fold increase in new cases of skin cancer between 2017 to 2019. BCC cases were more prevalent than SCC and MM cases. There was also a significant association between skin cancer and occupation also the location of skin cancer as the risk factor for UV exposure. Nevertheless, further research involving larger samples or a multicenter approach is needed.

Trends in incidence of non-melanoma and melanoma skin cancers in central Serbia

Introduction/Objective. The incidence of both melanoma and non-melanoma skin cancers (NMSC) has been increasing over the past decades worldwide. NMSC is the most common cancer in white population and melanoma is one of the deadliest cancers today. The objective of the paper was to determine trends in age-standardized incidence rates of NMSC and melanoma in central Serbia from 1999 to 2013. Method. A descriptive epidemiological study was done. Data about incidence for NMSC and melanoma were obtained from the Serbian Cancer Registry and data about population originating from 1991, 2001, and 2011 censuses. Crude incidence rates were calculated per 100,000 inhabitants. Direct method of standardization was performed with the world population as the standard. Trend lines were estimated using linear regression. Results. During a 15-year period, the total number of new NMSC cases was 41,719 [21,690 (52%) in men and 20,029 (48%) in women]. There were 5,781 new cases of melanoma [2,969 (51.4%) in men and 2,812 (48.6%) in women]. A significantly increasing incidence trend for NMSC both in men (y = 0.617x + 24.29, R2 = 0.500) and women (y = 0.672x + 0.670, R2 = 0.670) was determined. In the same period, a statistically significant increase of incidence trend for melanoma was determined in men (y = 0.111x + 3.708, R2 = 0.384) and in women (y = 0.098x + 3.375, R2 = 0.409). NMSC was registered in persons of all ages. NMSC incidence increased rapidly in persons older than 50 years. Melanoma predominates in children and adolescents and is registered more frequently than NMSC in persons bellow 60 years of age. Conclusion. Our findings showed significantly increasing trend of age-standardized incidence rates for both NMCC and melanoma. In the observed period, there were 7.2 times more new cases of NMSC than melanoma in the population of central Serbia. There were more registered new cases of NMSC and melanoma in men than in women. Screening of skin cancers and earlier diagnosis may improve treatment and prognosis.

PDT Brazil - Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences

s / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375 373 PDT Brazil Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences Romero Paulina1,2, Cabrera Franklin1,2, Tello Sonia1,2, Kurachi Cristina1,2, Ramirez Patricia1,2, Guaman Leonel1,2, Avalos Eduardo1,2, Bagnato Vanderlei1,2 1 Escuela Politecnica Nacional, Departamento de Materiales, Electrica y Fisica Quito-Ecuador. Hospital Carlos Andrade Marin, Servicio de Dermatologia e Histopatologia. Quito – Ecuador 2 Sao Carlos Institute of Physics, University of Sao Paulo, Brazil In Ecuador the National Tumor Registry (RNT) show in 2002 the non-melanoma skin cancer was the second most common cancer in men and women, but in 2005 it takes the first place for women. Experience: 11 patients with surface CBC, 47 with nodular CBC, 2 with CBC recurrences (depht middle dermis), 2 with CBC recurrences (neural invasion) and 3 with surface CEC, were treated with Photodynamic therapy based inMetil -ALA 20% and the LINCE light source with 100 W/cm2, 635nm wavelength. During treatment was used the dermatoscopy to monitor lesions. The results were evaluated by histopathological studies where the initial depth of the lesions was evident. These assessments allowed to find the depth at which treatment is efficient. Patients were treated between 2012 2014 in the “Carlos Andrade Marin” Hospital and “Gonzalo Gonzalez” Dermatological Hospital in QuitoEcuador. Results: After 2 therapy sessions for suface CBC (depht middle dermis) 90% of the patients have a complete response, for nodular CBC after 4 sessions 86% of the patients have a complete response, for the CBC recurrences (neural invasion) don’t show an effective response, and for surface CEC after 6 sessions 100% of the patients have a complete response. http://dx.doi.org/10.1016/j.pdpdt.2015.07.186 PDT Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months L.I.S. Mota, M.F.M. Brito, J.S. Belo Universidade Federal de Pernambuco Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months. Fundamentals: Basal-cell cancer is the most prevalent non-melanoma skin cancer in Brazil andworldwide. Photodynamic therapy (PDT) is a noninvasive technique with excellent cosmetic outcome and curative results. Maintaining cure rates remains an object of study due to the recent introduction of this therapy in dermatology. Objective: Evaluate the clinical response of photodynamic therapy in superficial basal-cell carcinoma after 12 months of treatment in patients with initial complete response at the end of the third month after treatment. Methods: After curettage and application of methyl aminolevulinate, the lesion was occluded for 3 hours. Then it was discovered and submitted a 635nm LED (37 J/cm2), positioned eight centimeters from the patient, for eight minutes. Two sessions were realized with intervals of 14 days. Pictures were performed before treatment, at 3 and 12 months after treatment. Results: The analyses involved 35 patients, that were submitted a MAL-PDT and presented complete response in the evaluation of three months. These cancers were checked with 12 months. A maintenance of complete clinical response was observed in 85% (30/35). Conclusion: PDT-MAL is a safe and effective therapeutic approach in the treatment of superficial BCC, with maintenance http://dx.doi.org/10.1016/j.pdpdt.2015.07.187 PDT Brazil A New Approach for Basal Cell Carcinoma Treatment Kate C. Blanco, Natalia M. Inada, Ana Paula da Silva, Pedro Russignoli, Dora P. Ramirez, Hilde H. Buzza, Mirian D. Stringasci, Lilian T. Moriyama, Clovis Grecco, Cristina Kurachi, Vanderlei S. Bagnato Sao Carlos Institute of Physics, University of Sao Paulo, Brazil Non-melanomaskin cancer (NMSC) is themostprevalent cancer type in Brazil andworldwide. According to the National Institute of Cancer (INCA) at the last year, it was estimated 182,130 new cases of NMSC in Brazil. Photodynamic Therapy (PDT) has proven to be effective with an excellent cosmetic outcome and reliable treatment option. A Brazilian programwas established to determine the efficacy of topicalMAL-PDTusing a Brazilian device (LINCE,MMOptics, Brazil) and medication (methyl aminolevulinate, PDTPharma, Brazil). During four years with financial support by BNDES (Brazilian Development Bank), we are reporting the treatment of 994 basal cell carcinoma (BCC), around all country and Latin America. Through these data it was analyzed the efficiency of the treatment 30 days after the second PDT session. Were compared the gender, age, skin type, location and size of the lesions. The conclusion of this extensive and important project has shown the efficacy PDT with 81.7% of clearance of superficial BCC and 75.1% for nodular BCC, and a small relapse rate of 1.22%. http://dx.doi.org/10.1016/j.pdpdt.2015.07.188 Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT Ana Gabriela Salvio1, Pedro E Russignoli 2, Natalia Mayumi Inada2, Elisangela Ramos de Oliveira1, Cristina Kurachi2, Vanderlei Salvador Bagnato2 1 Skin Deppartment of Amaral Carvalho Hospital, Brazil 2 Sao Carlos Institute of Physics, University of Sao

PDT Brazil - A New Approach for Basal Cell Carcinoma Treatment

s / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375 373 PDT Brazil Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences Romero Paulina1,2, Cabrera Franklin1,2, Tello Sonia1,2, Kurachi Cristina1,2, Ramirez Patricia1,2, Guaman Leonel1,2, Avalos Eduardo1,2, Bagnato Vanderlei1,2 1 Escuela Politecnica Nacional, Departamento de Materiales, Electrica y Fisica Quito-Ecuador. Hospital Carlos Andrade Marin, Servicio de Dermatologia e Histopatologia. Quito – Ecuador 2 Sao Carlos Institute of Physics, University of Sao Paulo, Brazil In Ecuador the National Tumor Registry (RNT) show in 2002 the non-melanoma skin cancer was the second most common cancer in men and women, but in 2005 it takes the first place for women. Experience: 11 patients with surface CBC, 47 with nodular CBC, 2 with CBC recurrences (depht middle dermis), 2 with CBC recurrences (neural invasion) and 3 with surface CEC, were treated with Photodynamic therapy based inMetil -ALA 20% and the LINCE light source with 100 W/cm2, 635nm wavelength. During treatment was used the dermatoscopy to monitor lesions. The results were evaluated by histopathological studies where the initial depth of the lesions was evident. These assessments allowed to find the depth at which treatment is efficient. Patients were treated between 2012 2014 in the “Carlos Andrade Marin” Hospital and “Gonzalo Gonzalez” Dermatological Hospital in QuitoEcuador. Results: After 2 therapy sessions for suface CBC (depht middle dermis) 90% of the patients have a complete response, for nodular CBC after 4 sessions 86% of the patients have a complete response, for the CBC recurrences (neural invasion) don’t show an effective response, and for surface CEC after 6 sessions 100% of the patients have a complete response. http://dx.doi.org/10.1016/j.pdpdt.2015.07.186 PDT Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months L.I.S. Mota, M.F.M. Brito, J.S. Belo Universidade Federal de Pernambuco Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months. Fundamentals: Basal-cell cancer is the most prevalent non-melanoma skin cancer in Brazil andworldwide. Photodynamic therapy (PDT) is a noninvasive technique with excellent cosmetic outcome and curative results. Maintaining cure rates remains an object of study due to the recent introduction of this therapy in dermatology. Objective: Evaluate the clinical response of photodynamic therapy in superficial basal-cell carcinoma after 12 months of treatment in patients with initial complete response at the end of the third month after treatment. Methods: After curettage and application of methyl aminolevulinate, the lesion was occluded for 3 hours. Then it was discovered and submitted a 635nm LED (37 J/cm2), positioned eight centimeters from the patient, for eight minutes. Two sessions were realized with intervals of 14 days. Pictures were performed before treatment, at 3 and 12 months after treatment. Results: The analyses involved 35 patients, that were submitted a MAL-PDT and presented complete response in the evaluation of three months. These cancers were checked with 12 months. A maintenance of complete clinical response was observed in 85% (30/35). Conclusion: PDT-MAL is a safe and effective therapeutic approach in the treatment of superficial BCC, with maintenance http://dx.doi.org/10.1016/j.pdpdt.2015.07.187 PDT Brazil A New Approach for Basal Cell Carcinoma Treatment Kate C. Blanco, Natalia M. Inada, Ana Paula da Silva, Pedro Russignoli, Dora P. Ramirez, Hilde H. Buzza, Mirian D. Stringasci, Lilian T. Moriyama, Clovis Grecco, Cristina Kurachi, Vanderlei S. Bagnato Sao Carlos Institute of Physics, University of Sao Paulo, Brazil Non-melanomaskin cancer (NMSC) is themostprevalent cancer type in Brazil andworldwide. According to the National Institute of Cancer (INCA) at the last year, it was estimated 182,130 new cases of NMSC in Brazil. Photodynamic Therapy (PDT) has proven to be effective with an excellent cosmetic outcome and reliable treatment option. A Brazilian programwas established to determine the efficacy of topicalMAL-PDTusing a Brazilian device (LINCE,MMOptics, Brazil) and medication (methyl aminolevulinate, PDTPharma, Brazil). During four years with financial support by BNDES (Brazilian Development Bank), we are reporting the treatment of 994 basal cell carcinoma (BCC), around all country and Latin America. Through these data it was analyzed the efficiency of the treatment 30 days after the second PDT session. Were compared the gender, age, skin type, location and size of the lesions. The conclusion of this extensive and important project has shown the efficacy PDT with 81.7% of clearance of superficial BCC and 75.1% for nodular BCC, and a small relapse rate of 1.22%. http://dx.doi.org/10.1016/j.pdpdt.2015.07.188 Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT Ana Gabriela Salvio1, Pedro E Russignoli 2, Natalia Mayumi Inada2, Elisangela Ramos de Oliveira1, Cristina Kurachi2, Vanderlei Salvador Bagnato2 1 Skin Deppartment of Amaral Carvalho Hospital, Brazil 2 Sao Carlos Institute of Physics, University of Sao

Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT

s / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375 373 PDT Brazil Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences Romero Paulina1,2, Cabrera Franklin1,2, Tello Sonia1,2, Kurachi Cristina1,2, Ramirez Patricia1,2, Guaman Leonel1,2, Avalos Eduardo1,2, Bagnato Vanderlei1,2 1 Escuela Politecnica Nacional, Departamento de Materiales, Electrica y Fisica Quito-Ecuador. Hospital Carlos Andrade Marin, Servicio de Dermatologia e Histopatologia. Quito – Ecuador 2 Sao Carlos Institute of Physics, University of Sao Paulo, Brazil In Ecuador the National Tumor Registry (RNT) show in 2002 the non-melanoma skin cancer was the second most common cancer in men and women, but in 2005 it takes the first place for women. Experience: 11 patients with surface CBC, 47 with nodular CBC, 2 with CBC recurrences (depht middle dermis), 2 with CBC recurrences (neural invasion) and 3 with surface CEC, were treated with Photodynamic therapy based inMetil -ALA 20% and the LINCE light source with 100 W/cm2, 635nm wavelength. During treatment was used the dermatoscopy to monitor lesions. The results were evaluated by histopathological studies where the initial depth of the lesions was evident. These assessments allowed to find the depth at which treatment is efficient. Patients were treated between 2012 2014 in the “Carlos Andrade Marin” Hospital and “Gonzalo Gonzalez” Dermatological Hospital in QuitoEcuador. Results: After 2 therapy sessions for suface CBC (depht middle dermis) 90% of the patients have a complete response, for nodular CBC after 4 sessions 86% of the patients have a complete response, for the CBC recurrences (neural invasion) don’t show an effective response, and for surface CEC after 6 sessions 100% of the patients have a complete response. http://dx.doi.org/10.1016/j.pdpdt.2015.07.186 PDT Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months L.I.S. Mota, M.F.M. Brito, J.S. Belo Universidade Federal de Pernambuco Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months. Fundamentals: Basal-cell cancer is the most prevalent non-melanoma skin cancer in Brazil andworldwide. Photodynamic therapy (PDT) is a noninvasive technique with excellent cosmetic outcome and curative results. Maintaining cure rates remains an object of study due to the recent introduction of this therapy in dermatology. Objective: Evaluate the clinical response of photodynamic therapy in superficial basal-cell carcinoma after 12 months of treatment in patients with initial complete response at the end of the third month after treatment. Methods: After curettage and application of methyl aminolevulinate, the lesion was occluded for 3 hours. Then it was discovered and submitted a 635nm LED (37 J/cm2), positioned eight centimeters from the patient, for eight minutes. Two sessions were realized with intervals of 14 days. Pictures were performed before treatment, at 3 and 12 months after treatment. Results: The analyses involved 35 patients, that were submitted a MAL-PDT and presented complete response in the evaluation of three months. These cancers were checked with 12 months. A maintenance of complete clinical response was observed in 85% (30/35). Conclusion: PDT-MAL is a safe and effective therapeutic approach in the treatment of superficial BCC, with maintenance http://dx.doi.org/10.1016/j.pdpdt.2015.07.187 PDT Brazil A New Approach for Basal Cell Carcinoma Treatment Kate C. Blanco, Natalia M. Inada, Ana Paula da Silva, Pedro Russignoli, Dora P. Ramirez, Hilde H. Buzza, Mirian D. Stringasci, Lilian T. Moriyama, Clovis Grecco, Cristina Kurachi, Vanderlei S. Bagnato Sao Carlos Institute of Physics, University of Sao Paulo, Brazil Non-melanomaskin cancer (NMSC) is themostprevalent cancer type in Brazil andworldwide. According to the National Institute of Cancer (INCA) at the last year, it was estimated 182,130 new cases of NMSC in Brazil. Photodynamic Therapy (PDT) has proven to be effective with an excellent cosmetic outcome and reliable treatment option. A Brazilian programwas established to determine the efficacy of topicalMAL-PDTusing a Brazilian device (LINCE,MMOptics, Brazil) and medication (methyl aminolevulinate, PDTPharma, Brazil). During four years with financial support by BNDES (Brazilian Development Bank), we are reporting the treatment of 994 basal cell carcinoma (BCC), around all country and Latin America. Through these data it was analyzed the efficiency of the treatment 30 days after the second PDT session. Were compared the gender, age, skin type, location and size of the lesions. The conclusion of this extensive and important project has shown the efficacy PDT with 81.7% of clearance of superficial BCC and 75.1% for nodular BCC, and a small relapse rate of 1.22%. http://dx.doi.org/10.1016/j.pdpdt.2015.07.188 Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT Ana Gabriela Salvio1, Pedro E Russignoli 2, Natalia Mayumi Inada2, Elisangela Ramos de Oliveira1, Cristina Kurachi2, Vanderlei Salvador Bagnato2 1 Skin Deppartment of Amaral Carvalho Hospital, Brazil 2 Sao Carlos Institute of Physics, University of Sao

Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study

X-ray repair cross-complementing group 1 (XRCC1) and group 3 (XRCC3) polymorphisms are relatively frequent in Caucasian populations and may have implications in skin cancer modulation. A few studies have evaluated their association with non-melanoma skin cancer (NMSC), but the results are inconsistent. In the current study, we aim to assess the impact of XRCC1 R399Q and XRCC3 T241M polymorphisms on the risk of NMSC associated with sunlight and arsenic exposure. Study participants consist of 618 new cases of NMSC and 527 hospital-based controls frequency matched on age, sex, and county of residence from Hungary, Romania, and Slovakia. Adjusted effects are estimated using multivariable logistic regression. The results indicate an increased risk of squamous cell carcinoma (SCC) for the homozygous variant genotype of XRCC1 R399Q (OR 2.53, 95% CI 1.14–5.65) and a protective effect against basal cell carcinoma (BCC) for the homozygous variant genotype of XRCC3 T241M (OR 0.61, 95% CI 0.41–0.92), compared with the respective homozygous common genotypes. Significant interactions are detected between XRCC3 T241M and sunlight exposure at work, and between XRCC3 T241M and exposure to arsenic in drinking water (p-value for interaction <0.10). In conclusion, the current study demonstrates that polymorphisms in XRCC genes may modify the associations between skin cancer risk and exposure to sunlight or arsenic. Given the high prevalence of genetic polymorphisms modifying the association between exposure to environmental carcinogens and NMSC, these results are of substantial relevance to public health.

Skin Cancer (Basal Cell Carcinoma, Squamous Cell Carcinoma, and Malignant Melanoma): New Cases, Treatment Practice, and Health Care Costs in New Brunswick, Canada, 2002–2010

In Canada, there is no formal process for registering nonmelanoma skin cancer (NMSC); thus, the epidemiology, treatment practices, and associated health costs are not well known. To investigate trends in new cases of skin cancer, treatment practices, and health care costs in New Brunswick, Canada. Data were extracted from the Provincial Cancer Registry and New Brunswick administrative health databases for 2002-2010. New cases: Basal Cell Carcinoma (BCC) was the most common skin cancer diagnosed, and incidence rates significantly increased between 1992 and 2010.Treatment practice: Dermatologists managed the majority (45%) of the overall skin cancer treatments.Health care costs: NMSC accounted for ∼80% of the health care costs for skin cancer and was dominated by BCC. Development of best practice treatment guidelines for NMSC in New Brunswick would improve future health care efficiencies, and standard protocols for registering new cases of NMSC in Canada would strengthen surveillance and reporting capacity.

Câncer de pele: a importância do seu diagnóstico, tratamento e prevenção

Skin cancer is the most common disease in Caucasian all over the world. The non-melanoma skin cancer (NMSC) is responsible for more than 90% of all skin cancer. Data presents that the incidence of NMSC is currently increasing each year, especially among young people. The squamous cell carcinoma represents 25% of all NMSC and the basal cell carcinoma is more often diagnosed, corresponding 70% of the cases and may affect more than 1 million people every year. These estimates are increasing worldwide, and in Brazil this is not different. Only for this year, it has been estimated almost 200.000 new cases of NMSC, detecting an increase of 88% in the risk of developing NMSC after four years. Therefore, the physicians must be alert to identify a lesion of NMSC and to treat it correctly in order to avoid recurrence and persistence of the tumor. Considering that each NMSC lesions is one of a kind and its treatment must be directed to each patients, surgical and non-surgical techniques are been developed to reach the complete remission of the tumor, preserving the normal tissue, the function of the area committed by the tumor and to achieve a better aesthetic outcome. Therefore, learning about the NMSC development, diagnostic and treatment could impact in health system and contribute to prevent new cases.

Itch and Pain in Nonmelanoma Skin Cancer: Pain as an Important Feature of Cutaneous Squamous Cell Carcinoma

Pain is a common feature of cancer with an estimated prevalence rate between 52% and 77%.1 Itch is the most common dermatologic symptom and is also a common feature of lymphoma.2 However, no studies have been performed examining the prevalence rates of pain and itch in common skin cancers. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the 2 most common types of nonmelanoma skin cancer (NMSC). They have a rapidly increasing incidence in the United States, with nearly 4 million new cases of NMSC diagnosed each year.3 The purpose of the present study was to assess the prevalence and intensity of pain and itch among the 2 most common skin cancers.

Cost and patterns of care among patients with advanced non-melanoma skin cancer.

e16517 Background: Few studies examine health care utilization (HCU) and cost among basal cell carcinoma (BCC) patients. Although BCC has no specific ICD-9 code, it is known to constitute ~80% of all non-melanoma skin cancers (NMSC). More than 1 million new cases of NMSC were reported in the US in 2010, and there were ~1000 deaths due to NMSC. Methods: A claims-based analysis was conducted using data from January 2002 to March 2010 from a national commercial health insurer. Patients with ≥ 2 claims with a NMSC diagnosis (ICD-9-CM 173.xx) at least 60 days apart, or at least 1 claim for a skin cancer-specific excision with diagnosis code 173.xx were identified. Those with additional primary cancers were excluded. Patients were grouped into 1 of 3 cohorts: metastatic, locally advanced (LA), or “all other.” Metastatic patients had ≥ 2 claims with a metastasis code (ICD-9-CM 196.xx-198.xx) at least 30 days apart. LA patients had ≥ 2 visits with a medical oncologist, ≥ 1 diagnostic imaging service, ≥2 services for radiation therapy or ≥1 visit to 2 or more physician specialties. The remaining patients were “all other.” The time of first NMSC or metastatic disease diagnosis was considered the index date. Total HCU and average per-patient per-month (PPPM) costs during follow-up were estimated. Results: Among 188,795 patients, 155 (0.1%), 2,412 (1.3%) and 186,228 (98.6%) patients, were identified as metastatic, LA or “all other,” respectively with an overall mean follow-up of 917 days. Compared to “all others,” metastatic and LA patients were significantly older and had a higher baseline Charlson comorbidity index (0.64 vs. 2.08 and 1.46 respectively, p-value <0.01). Compared to “all others” and LA patients, more metastatic patients had inpatient stays (19% and 30% vs. 48% respectively, p-value <0.01) and emergency room visits (37% and 43% vs. 55% respectively, p-value <0.01). In addition, total PPPM costs for LA and metastatic patients were ~2x or ~3x higher, respectively, than costs for “all others (p-value <0.01). Conclusions: HCU and cost for NMSC (which includes ~80% BCC) increases significantly as disease advances. Effective treatment could reduce this burden.

The needs and experiences of people with a diagnosis of skin cancer.

Objectives The aim is to conduct a systematic review looking at the needs and experiences of people with a diagnosis of skin cancer. Criteria for considering studies for this review Types of participants This review will consider studies of people with skin cancer (non-melanoma skin cancer and melanoma skin cancer). Phenomena of Interest The phenomena of interest are the needs and experiences of people with skin cancer. Outcome of interest Outcomes of interest include peoples experience of having a skin cancer at any point of the cancer journey and afterwards.